Cancer Drugs Fund inquiry

Inquiry by the Public Accounts Committee, 3 November 2015 to 12 May 2016. Its page on the Parliament website.

Reports and responses

• 20th Report - Cancer Drugs Fund (5 February 2016)
• Government responses on the Fifteenth to the Twentieth reports from the Committee of Public Accounts: Session 2015-16 (23 March 2016)

Evidence sessions

• 30 November 2015: Mark Hicken, Managing Director, Johnson and Johnson, Deb Lancaster, Director of Market Access, Roche, and Harpal Kumar, Chief Executive, Cancer Research UK; Will Cavendish, Director General, Innovation, Growth and Technology, Department of Health, Simon Stevens, Chief Executive, and Professor Peter Clark, Chair of the Cancer Drugs Fund, NHS England, and Sir Andrew Dillon, Chief Executive, National Institute for Health and Clinical Excellence (at 4.30pm).